tirzepatide – Page 2

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

By MedXY 09/17/2025

The SUMMIT trial reveals that tirzepatide improves heart failure outcomes and quality of life in obese HFpEF patients with or without type 2 diabetes, despite attenuated weight loss in diabetic patients.

Clinical Updates Diabetes & Endocrinology news Specialties

Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study

By MedXY 09/17/2025

A 12-week prospective study demonstrates tirzepatide significantly improves insulin sensitivity in obese Japanese patients with type 2 diabetes, independent of weight loss, as assessed by hyperinsulinaemic-euglycaemic clamp.

Cardiology Clinical Updates news Specialties

Semaglutide and Tirzepatide Significantly Reduce Hospitalization and Mortality in Cardiometabolic HFpEF Patients: Real-World Evidence

By MedXY 08/31/2025

Real-world analysis shows semaglutide and tirzepatide reduce hospitalization for heart failure or all-cause mortality by over 40% in patients with cardiometabolic HFpEF, with no significant difference between the two drug options.

Diabetes & Endocrinology news Specialties

Tirzepatide Enhances Quality of Life in Adults with Obesity or Overweight: Insights from the SURMOUNT-3 Trial

By MedXY 08/30/2025

Tirzepatide significantly improves health-related quality of life alongside weight reduction in adults with obesity or overweight, especially those experiencing physical function limitations, according to SURMOUNT-3 trial results.

Diabetes & Endocrinology news Specialties

Tirzepatide Significantly Lowers Predicted 10-Year Type 2 Diabetes Risk in Chinese Adults with Overweight or Obesity: Insights from the SURMOUNT-CN Trial

By MedXY 08/30/2025

Post hoc analysis of the SURMOUNT-CN trial shows tirzepatide markedly reduces the 10-year predicted risk of type 2 diabetes in Chinese individuals with overweight or obesity, regardless of baseline BMI or prediabetes status.

Cardiology Diabetes & Endocrinology news Specialties

Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial

By MedXY 08/17/2025

Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.

Diabetes & Endocrinology news OB/GYN & Women's Health Specialties

Enhanced Weight Loss for Menopausal Women: The Role of Tirzepatide and Hormone Therapy

By MedXY 07/29/2025

A new study reveals combining tirzepatide and hormone therapy significantly boosts weight loss in postmenopausal women, offering a promising approach to managing obesity-related health risks.

Diabetes & Endocrinology news

The End of the Diet? Inside the Game-Changing Anti-Obesity Drug Revolution

By MedXY 07/25/2025

New anti-obesity medications are transforming weight management, challenging old paradigms, and raising new questions about the future of dieting and health.